IP Library › Granted Patent US 11,517,595
Granted Patent B2
US 11,517,595 · App. 16/226,344 · Granted Dec 6, 2022

Methods of microbial treatment of poultry

Inventors: Thomas Rehberger (Wauwatosa, WI); Evan Hutchison (Milwaukee, WI); Alexandra Smith (Greendale, WI); Joshua Rehberger (Milwaukee, WI)
Assignee: Church & Dwight Co., Inc.
A61K35/742A23K10/10A23K10/18A23K50/70A23K50/75A61K38/164A61K2035/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,517,595
App. No.
16/226,344
Granted
Dec 6, 2022
Kind
B2
Abstract

Disclosed are methods of administering one or more Bacillus strains to poultry. The Bacillus strains improve bacterial homeostasis in the gastrointestinal tract by inhibiting bacterial pathogens such as E. coli and Clostridium . Administering the Bacillus strains also improves performance such as weight gain and feed conversion. Useful combinations of Bacillus strains and methods of using one or more Bacillus strains are also provided.

Claims (22)

1. A microbial composition comprising

(a) at least one isolated Bacillus strain chosen from at least one of strains Bacillus subtilis 1104, deposited as NRRL B-67258; Bacillus subtilis 1781, deposited as NRRL B-67259; Bacillus subtilis 747, deposited as NRRL B-67257; Bacillus subtilis 1541, deposited as NRRL B-67260; and Bacillus subtilis 2018, deposited as NRRL B-67261; present in a concentration of about 10 5 CFU/gram to about 10 12 CFU/gram; and

(b) a carrier;

wherein the composition inhibits a pathogen chosen from at least one of E. coli and Clostridium when administered to an animal,

wherein the composition is a freeze-dried composition, a spray-dried composition, or a fluidized bed dried composition.

2. The microbial composition of claim 1 , wherein the carrier is selected from a group consisting of: whey, maltodextrin, sucrose, dextrose, limestone, rice hulls, and sodium silica aluminate.

3. The microbial composition of claim 2 , wherein the carrier is in the physical form of a powdered solid.

4. An animal feed comprising the microbial composition of claim 1 , wherein the microbial composition has concentration of the at least one isolated Bacillus strain in the composition of about 1×10 8 CFU/g.

5. A direct fed microbial composition comprising

(a) at least one isolated Bacillus strain chosen from at least one of strains Bacillus subtilis 1104, deposited as NRRL B-67258; Bacillus subtilis 1781, deposited as NRRL B-67259; Bacillus subtilis 747, deposited as NRRL B-67257; Bacillus subtilis 1541, deposited as NRRL B-67260; and Bacillus subtilis 2018, deposited as NRRL B-67261 present in a concentration of about 10 5 CFU/gram to about 10 12 CFU/gram; and

(b) a carrier;

wherein the composition inhibits a pathogen chosen from at least one of E. coli and Clostridium in an animal, and

wherein the composition is a freeze-dried composition, a spray-dried composition, or a fluidized bed dried composition.

6. The direct fed microbial composition of claim 5 , wherein the composition comprises a plurality of isolated Bacillus strains chosen from the strains Bacillus subtilis 1104, deposited as NRRL B-67258; Bacillus subtilis 1781, deposited as NRRL B-67259; Bacillus subtilis 747, deposited as NRRL B-67257; Bacillus subtilis 1541, deposited as NRRL B-67260; and Bacillus subtilis 2018, deposited as NRRL B-67261.

7. The direct fed microbial composition of claim 5 , wherein the carrier is selected from a group consisting of: whey, maltodextrin, sucrose, dextrose, limestone, rice hulls, and sodium silica aluminate.

8. A direct fed microbial composition comprising

(a) at least one isolated Bacillus strain is chosen from at least one of strains Bacillus subtilis 1104, deposited as NRRL B-67258; Bacillus subtilis 1781, deposited as NRRL B-67259; Bacillus subtilis 747, deposited as NRRL B-67257; Bacillus subtilis 1541, deposited as NRRL B-67260; Bacillus subtilis 1999, deposited as NRRL B-67318; and Bacillus subtilis 2018, deposited as NRRL B-67261 present in a concentration of about 10 5 CFU/gram to about 10 12 CFU/gram; and

(b) a carrier;

wherein the at least one isolated Bacillus strain inhibits a pathogen chosen from at least one of E. coli and Clostridium in an animal, and

wherein the composition is a freeze-dried composition, a spray-dried composition, or a fluidized bed dried composition.

9. The direct fed microbial composition of claim 8 , wherein the composition comprises a plurality of isolated Bacillus strains chosen from the strains Bacillus subtilis 1104, deposited as NRRL B-67258; Bacillus subtilis 1781, deposited as NRRL B-67259; Bacillus subtilis 747, deposited as NRRL B-67257; Bacillus subtilis 1541, deposited as NRRL B-67260; Bacillus subtilis 1999, deposited as NRRL B-67318; and Bacillus subtilis 2018, deposited as NRRL B-67261.

10. The direct fed microbial composition of claim 8 , wherein the carrier is selected from a group consisting of: whey, maltodextrin, sucrose, dextrose, limestone, rice hulls, and sodium silica aluminate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2021
From: REHBERGER, THOMAS; HUTCHISON, EVAN; SMITH, ALEXANDRA; REHBERGER, JOSHUA
To: AGRO BIOSCIENCES, INC.
Reel/Frame 058007/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2021
From: AGRO BIOSCIENCES, INC.
To: CHURCH & DWIGHT CO., INC.
Reel/Frame 058007/0847 →
Continuity (3)
Division 15268104 · Sep 16, 2016
Provisional Application 62219433 · Sep 16, 2015
Related Publication 20190231828A1 · Aug 1, 2019